US20020055177A1
(en)
*
|
1999-03-10 |
2002-05-09 |
Glaxo Wellcome Inc. |
Compound and its use
|
US6639072B1
(en)
|
2000-01-03 |
2003-10-28 |
Rpg Life Sciences Limited |
Process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
|
AT5874U1
(de)
|
2000-12-29 |
2003-01-27 |
Bioorg Bv |
Pharmazeutische zubereitungen enthaltend amlodipinmaleat
|
US7335380B2
(en)
|
2000-12-29 |
2008-02-26 |
Synthon Ip Inc. |
Amlodipine free base
|
GB2371862B
(en)
*
|
2000-12-29 |
2004-07-14 |
Bioorg Bv |
Reference standards for determining the purity or stability of amlodipine maleate and processes therefor
|
BR0116553A
(pt)
|
2000-12-29 |
2004-02-03 |
Pfizer Ltd |
Composto, composição farmacêutica para tratamento de angina ou hipertensão, processo, processo para tratamento ou prevenção de angina ou hipertensão, composição de ingredientes farmaceuticamente ativos, composição farmacêutica para tratamento ou prevenção de angina ou hipertensão e processo para tratar ou prevenir angina ou hipertensão
|
US6653481B2
(en)
|
2000-12-29 |
2003-11-25 |
Synthon Bv |
Process for making amlodipine
|
BR0116557A
(pt)
|
2000-12-29 |
2003-10-28 |
Pfizer Ltd |
Processo, processo para fabricação de um sal de maleato de amlodipina substancialmente livre de aspartato de amlodipina, processo para purificação, maleato de amlodipina, composição farmacêutica para tratar ou prevenir angina ou hipertenção, método para tratar hipertenção, angina ou ataque cardìaco, benzeno sulfonato de amlodipina, hidrocloreto de amlodipina e uso de maleato de amlodipina substancialmente livre de aspartato de amlodipina
|
EP1309556B1
(fr)
|
2000-12-29 |
2004-11-24 |
Pfizer Limited |
Fumarate d'amlodipine
|
MXPA03005882A
(es)
|
2000-12-29 |
2005-04-19 |
Pfizer Ltd |
Derivado amida de amlodipina.
|
EP1309554A1
(fr)
|
2000-12-29 |
2003-05-14 |
Synthon Licensing, Ltd. |
Derive d'amide d'amlodipine
|
DE60116514T2
(de)
|
2000-12-29 |
2006-08-17 |
Pfizer Ltd., Sandwich |
Amlodipinhemimaleat
|
DE10134980C2
(de)
*
|
2001-07-17 |
2003-05-28 |
Helm Ag |
Verfahren zur Herstellung von Lamotrigin
|
CA2366521C
(fr)
|
2001-12-24 |
2007-03-06 |
Brantford Chemicals Inc. |
Un procede nouveau et efficace de preparation de lamotrigine et d'autres 3,5-diamino-1,2,4-triazines substituees en position 6
|
CA2479668A1
(fr)
*
|
2002-03-20 |
2003-10-02 |
Teva Pharmaceutical Industries Ltd. |
Formes cristallines d'hemifumarate de quetiapine
|
HU225667B1
(en)
|
2002-09-20 |
2007-05-29 |
Richter Gedeon Nyrt |
Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
|
ES2209639B1
(es)
|
2002-10-31 |
2005-08-01 |
Vita Cientifica, S.L. |
Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
|
GB2395483A
(en)
*
|
2003-07-03 |
2004-05-26 |
Jubilant Organosys Ltd |
Crystalline lamotrigine and its monohydrate
|
EP1562912A2
(fr)
|
2003-08-28 |
2005-08-17 |
Teva Pharmaceutical Industries Limited |
Procede de preparation de sels calciques de rosuvastatine
|
EP1601658A1
(fr)
*
|
2003-11-24 |
2005-12-07 |
Teva Pharmaceutical Industries Limited |
Sels d'ammonium cristallins de la rosuvastatine
|
ATE507209T1
(de)
*
|
2003-12-02 |
2011-05-15 |
Teva Pharma |
Referenzstandard zur charakterisierung von rosuvastatin
|
US7851624B2
(en)
*
|
2003-12-24 |
2010-12-14 |
Teva Pharamaceutical Industries Ltd. |
Triol form of rosuvastatin and synthesis of rosuvastatin
|
EP1709002A2
(fr)
*
|
2004-01-30 |
2006-10-11 |
Teva Pharmaceutical Industries Ltd. |
Montelukast de sodium polymorphe
|
US20050187243A1
(en)
*
|
2004-01-30 |
2005-08-25 |
Valerie Niddam-Hildesheim |
Montelukast free acid polymorphs
|
MD2823G2
(ro)
*
|
2004-02-12 |
2006-05-31 |
Институт Химии Академии Наук Молдовы |
Procedeu de determinare cantitativă a sclareolului în extractele, obţinute din salvia de muscat
|
DE602005015174D1
(de)
*
|
2004-04-21 |
2009-08-13 |
Teva Pharma |
Verfahren zur herstellung von montelukast-natrium
|
JP2007532585A
(ja)
|
2004-04-26 |
2007-11-15 |
テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ |
ミコフェノール酸及びそのエステル誘導体の調製方法
|
WO2005105769A2
(fr)
*
|
2004-04-27 |
2005-11-10 |
Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg - |
Impureté du mofétilmycophénolate
|
US7439399B2
(en)
*
|
2004-06-28 |
2008-10-21 |
Teva Pharmaceutical Fine Chemicals |
Processes for the preparation of atomoxetine hydrochloride
|
US7317127B2
(en)
*
|
2004-06-28 |
2008-01-08 |
Teva Pharmaceutical Fine Chemicals S.R.L |
Process for the optical resolution and recycling of tomoxetine
|
EP1673351A1
(fr)
*
|
2004-07-13 |
2006-06-28 |
Teva Pharmaceutical Industries Ltd. |
Procede pour la preparation de rosuvastatin comprenant une etape d'oxydation mediee par tempo
|
ES2340184T3
(es)
*
|
2004-07-20 |
2010-05-31 |
Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag |
Micofenolato sodico cristalino.
|
WO2006020348A2
(fr)
*
|
2004-07-22 |
2006-02-23 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Polymorphes du chlorhydrate d'atomoxetine
|
CA2578750A1
(fr)
*
|
2004-09-04 |
2006-03-16 |
Teva Pharmaceutical Industries, Ltd. |
Support conditionne de cellules progenitrices autologues ou allogenes pour traitement de l'angiogenese
|
US20060081361A1
(en)
*
|
2004-09-13 |
2006-04-20 |
Gabbey Lawrence W |
Oil cooler with integral filter
|
TWI321132B
(en)
*
|
2004-09-28 |
2010-03-01 |
Teva Pharma |
Process for preparing forms of atorvastatin calcium substantially free of impurities
|
JP2007514777A
(ja)
*
|
2004-10-19 |
2007-06-07 |
テバ ファーマシューティカル インダストリーズ リミティド |
テガセロッドマレエートの精製
|
US7678551B2
(en)
*
|
2004-10-25 |
2010-03-16 |
Seradyn, Inc. |
Immunoassays for lamotrigine
|
JP2007523213A
(ja)
*
|
2004-12-23 |
2007-08-16 |
テバ ファーマシューティカル インダストリーズ リミティド |
医薬的に許容できるデュロキセチンの塩及びその中間体の調製方法
|
ES2334579T3
(es)
*
|
2005-01-11 |
2010-03-12 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Procedimiento para la preparacion del clorhidrato de 1-amino-3,5-dimetil-adamantano.
|
US20070167625A1
(en)
*
|
2005-02-22 |
2007-07-19 |
Anna Balanov |
Preparation of rosuvastatin
|
US20070037979A1
(en)
*
|
2005-02-22 |
2007-02-15 |
Valerie Niddam-Hildesheim |
Preparation of rosuvastatin
|
CA2591439C
(fr)
*
|
2005-02-22 |
2013-03-26 |
Teva Pharmaceutical Industries Ltd. |
Rosuvastatine, sels de rosuvastatine exempts de son alkylether, procede d'elaboration correspondant
|
US7291614B2
(en)
*
|
2005-02-24 |
2007-11-06 |
Teva Pharmaceutical Industries Ltd. |
Processes for the preparation of linezolid intermediate
|
WO2006099459A1
(fr)
*
|
2005-03-14 |
2006-09-21 |
Teva Pharmaceutical Industries Ltd. |
Procede de preparation du compose optiquement actif (s)-(+)-n,n-dimethyl-3-(1-naphtalenyloxy)-3-(2-thienyl)propanamine
|
US7569729B2
(en)
*
|
2005-04-05 |
2009-08-04 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Stable atomoxetine hydrochloride, a process for the preparation thereof, and an analytical control of its stability
|
WO2006108151A1
(fr)
*
|
2005-04-06 |
2006-10-12 |
Teva Pharmaceutical Industries Ltd. |
Formes cristallines de pregabaline
|
EP1768950A2
(fr)
*
|
2005-04-11 |
2007-04-04 |
Teva Pharmaceutical Industries Ltd. |
Procede de fabrication de (s)-pregabaline
|
US7488846B2
(en)
*
|
2005-04-11 |
2009-02-10 |
Teva Pharmaceuical Industries Ltd. |
Pregabalin free of lactam and a process for preparation thereof
|
WO2006113425A1
(fr)
*
|
2005-04-14 |
2006-10-26 |
Teva Pharmaceutical Industries Ltd. |
Processus de preparation de fumarate de quetiapine
|
US20080281111A1
(en)
*
|
2005-04-26 |
2008-11-13 |
Sandor Molnar |
Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
|
MX2007000525A
(es)
*
|
2005-05-10 |
2007-03-28 |
Teva Pharma |
Pregabalina libre de acido isobutilglutarico y un proceso para la preparacion de ella.
|
ATE486841T1
(de)
*
|
2005-05-10 |
2010-11-15 |
Teva Pharma |
Verfahren zur herstellung von pregabalin und salzen daraus
|
EP1879852A1
(fr)
*
|
2005-05-10 |
2008-01-23 |
Teva Pharmaceutical Industries Ltd |
Pregabaline exempte de lactame et son procede de preparation
|
KR20070118305A
(ko)
*
|
2005-05-10 |
2007-12-14 |
테바 파마슈티컬 인더스트리즈 리미티드 |
3-카르바모일메틸-5-메틸 헥산산의 광학 분할
|
CN101180261A
(zh)
|
2005-05-23 |
2008-05-14 |
特瓦制药工业有限公司 |
用于制备盐酸西那卡塞晶型ⅰ的方法
|
US20070032660A1
(en)
*
|
2005-06-27 |
2007-02-08 |
Alessandro Pontiroli |
Purification process for Anastrozole intermediate
|
BRPI0611116A2
(pt)
*
|
2005-06-27 |
2010-08-10 |
Sicor Inc |
uma impureza de intermediário de anastrozol e seus usos
|
CA2608369A1
(fr)
*
|
2005-07-05 |
2007-01-11 |
Teva Pharmaceutical Industries Ltd. |
Purification du montelukast
|
WO2007022488A2
(fr)
*
|
2005-08-16 |
2007-02-22 |
Teva Pharmaceutical Industries Ltd. |
Intermediaire de rosuvastatine sous forme cristalline
|
KR20080034205A
(ko)
*
|
2005-09-19 |
2008-04-18 |
테바 파마슈티컬 인더스트리즈 리미티드 |
(s)-프레가발린의 신규한 합성을 위한 주요 중간체인 키랄3-카르바모일메틸-5-메틸 헥산산
|
US20070197529A1
(en)
*
|
2005-12-01 |
2007-08-23 |
Viviana Braude |
Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard
|
WO2007067581A1
(fr)
*
|
2005-12-05 |
2007-06-14 |
Teva Pharmaceutical Industries Ltd. |
2-(n-methyl-propanamine)-3-(2-naphtol)thiophene, une impurete du duloxetine chlorhydrate
|
WO2007069264A2
(fr)
*
|
2005-12-15 |
2007-06-21 |
Alembic Limited |
Nouveaux composes
|
US20070197630A1
(en)
*
|
2005-12-27 |
2007-08-23 |
Valeriano Merli |
Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
|
US20080033054A1
(en)
*
|
2006-03-27 |
2008-02-07 |
Valeriano Merli |
Process for preparing memantine hydrochloride substantially free of impurities
|
US20080146675A1
(en)
*
|
2006-04-05 |
2008-06-19 |
Eugenio Castelli |
Stable Atomoxetine Hydrochloride, a process for the preparation thereof, and an analytical control of its stability
|
GB0609835D0
(en)
*
|
2006-05-18 |
2006-06-28 |
Pliva Istrazivanje I Razvoj D |
Impurities of a pharmaceutical product
|
WO2007139933A2
(fr)
*
|
2006-05-24 |
2007-12-06 |
Teva Pharmaceutical Industries Ltd. |
Procédés pour la préparation d'acide r-(+)-3-(carbamoyl méthyl)-5-méthylhexanoïque et de sels de celui-ci
|
KR20080036060A
(ko)
*
|
2006-05-31 |
2008-04-24 |
테바 파마슈티컬 인더스트리즈 리미티드 |
프레가발린의 중간체의 제조에 효소 분할을 이용하는 방법
|
EP1912931A2
(fr)
*
|
2006-05-31 |
2008-04-23 |
Teva Pharmaceutical Industries Ltd. |
Préparation de (s)-prégabaline nitrile
|
WO2008002665A1
(fr)
*
|
2006-06-29 |
2008-01-03 |
Teva Pharmaceutical Industries Ltd. |
Régulation de la production de métabolites acides
|
US20120142919A1
(en)
*
|
2006-08-02 |
2012-06-07 |
Medichem, S.A. |
Method for synthesizing lamotrigine
|
CN101506178A
(zh)
*
|
2006-08-14 |
2009-08-12 |
隆沙有限公司 |
制备拉莫三嗪的方法
|
EP2139845A1
(fr)
*
|
2007-02-26 |
2010-01-06 |
Teva Pharmaceutical Industries Ltd. |
Intermédiaires et procédés pour la synthèse de ramelteon
|
TW200846308A
(en)
*
|
2007-03-22 |
2008-12-01 |
Teva Pharma |
Synthesis of (s)-(+)-3-(aminomethyl)-5-methyl hexanoic acid
|
US20080254520A1
(en)
*
|
2007-04-11 |
2008-10-16 |
Eva Gulyas |
Method for reducing impurity level in mycophenolic acid fermentation
|
US8084630B2
(en)
*
|
2007-05-31 |
2011-12-27 |
Teva Pharmaceutical Industries Ltd. |
Process for the synthesis of ramelteon and its intermediates
|
KR20090101462A
(ko)
*
|
2007-10-03 |
2009-09-28 |
테바 파마슈티컬 인더스트리즈 리미티드 |
프레가발린-4-엘리미네이트, 프레가발린 5-엘리미네이트, 기준 마커 및 표준물로서의 이들의 용도, 및 이들을 낮은 수준으로 함유하는 프레가발린의 제조 방법
|
PL2508523T5
(pl)
*
|
2007-10-23 |
2020-08-10 |
Teva Pharmaceutical Industries Ltd. |
Odmiany polimorficzne dasatynibu i sposób ich wytwarzania
|
WO2009056993A2
(fr)
*
|
2007-11-01 |
2009-05-07 |
Teva Pharmaceutical Industries Ltd. |
Procédé de synthèse de rameltéon et intermédiaires de ce dernier
|
US8486927B2
(en)
*
|
2007-11-09 |
2013-07-16 |
Thar Pharmaceuticals |
Crystalline forms of lamotrigine
|
CA2717580A1
(fr)
*
|
2008-03-06 |
2009-12-17 |
Teva Pharmaceutical Industries Ltd. |
Procedes de preparation de la o-desmethylvenlafaxine, exempte de ses impuretes dimeres
|
WO2009158343A1
(fr)
*
|
2008-06-23 |
2009-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Synthèse enzymatique stéréosélective de l’ester (s) ou (r)-isobutylglutarique
|
WO2010045565A1
(fr)
*
|
2008-10-16 |
2010-04-22 |
Teva Pharmaceutical Industries Ltd. |
Procédé de synthèse du ramelteon et de ses intermédiaires
|
EP2539313A2
(fr)
*
|
2010-03-29 |
2013-01-02 |
Pliva Hrvatska D.O.O. |
Formes cristallines du fumarate de o-desméthylvenlafaxine
|
WO2012034065A1
(fr)
|
2010-09-09 |
2012-03-15 |
Teva Pharmaceutical Industries Ltd. |
Intermédiaires d'aliskirène et procédé destiné à analyser la pureté de l'aliskirène
|
CN102766104A
(zh)
*
|
2012-08-20 |
2012-11-07 |
三金集团湖南三金制药有限责任公司 |
一种治疗双向情感障碍及癫痫病药物拉莫三嗪的合成方法
|
US10189859B2
(en)
|
2013-12-21 |
2019-01-29 |
Nektar Therapeutics |
Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
|
CN110467560A
(zh)
|
2018-05-09 |
2019-11-19 |
深圳微芯生物科技股份有限公司 |
一种苯基氨基丙酸钠衍生物、其制备方法和应用
|
KR102270026B1
(ko)
*
|
2020-01-31 |
2021-06-28 |
현대약품 주식회사 |
(3s)-3-(4-(3-(1,4-다이옥사스파이로[4,5]데스-7-엔-8-일)벤질옥시)페닐)헥스-4-이노익산의 품질 평가 방법
|
CN113156009B
(zh)
*
|
2021-04-20 |
2023-12-22 |
三金集团湖南三金制药有限责任公司 |
高效液相色谱分析拉莫三嗪的方法
|